Results 91 to 100 of about 423,899 (348)

The Glycobiology of Pulmonary Arterial Hypertension

Metabolites, 2022
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease of complex etiology. Cases of PAH that do not receive therapy after diagnosis have a low survival rate. Multiple reports have shown that idiopathic PAH, or IPAH, is associated with metabolic dysregulation including altered bioavailability of nitric oxide (NO) and ...
Shia Vang, Phillip Cochran, Julio Sebastian Domingo, Stefanie Krick, Jarrod Wesley Barnes   +4 more
openaire   +3 more sources

Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers

Advanced Healthcare Materials, EarlyView.
This perspective provides an overview of the growing interest in utilizing various gasotransmitters—small gaseous signaling molecules namely nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—for several therapeutic applications, with emphasis on the potential use of porous materials as carriers to provide safe and controlled local ...
Rosana V. Pinto, Moisés L. Pinto, Christian Serre   +2 more
wiley   +1 more source

Left ventricular torsion rate and the relation to right ventricular function in pediatric pulmonary arterial hypertension

Pulmonary Circulation, 2018
The right ventricle and left ventricle are physically coupled through the interventricular septum. Therefore, changes in the geometry and mechanics of one ventricle can directly affect the function of the other.
Melanie J. Dufva, Uyen Truong, Pawan Tiwari, Dunbar D. Ivy, Robin Shandas, Vitaly O. Kheyfets   +5 more
doaj   +1 more source

The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis [version 1; peer review: 2 approved]

F1000Research, 2019
Pulmonary arterial hypertension, categorized as group 1 pulmonary hypertension by the World Health Organization classification system, represents a major complication of systemic sclerosis resulting from pulmonary vascular involvement of the disease. The
Michael H Lee, Todd M Bull
doaj   +1 more source

Blockade of JAK2 protects mice against hypoxia‐induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation

Cell Proliferation, 2020
Hypoxia is an important risk factor for pulmonary arterial remodelling in pulmonary arterial hypertension (PAH), and the Janus kinase 2 (JAK2) is believed to be involved in this process.
Lei Zhang, Yi Wang, Guorao Wu, Lizong Rao, Yanqiu Wei, H. Yue, Ting Yuan, Ping Yang, Fei Xiong, Shu Zhang, Qing Zhou, Zhishui Chen, Jinxiu Li, B. Mo, Huilan Zhang, W. Xiong, Cong-Yi Wang   +16 more
semanticscholar   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source

Treatments for pulmonary arterial hypertension [PDF]

Respiratory Medicine, 2006
Pulmonary arterial hypertension (PAH) is a devastating disease that leads to right heart failure and premature death. Historically, we are restricted by limited options for drug treatment. Over the past decade, with advances in our understanding of pathophysiological and molecular mechanisms, many new therapeutic strategies (synthetic prostacyclin and ...
Kunshen Liu, Chao Liu, Zhenguo Ji, Gang Liu   +3 more
openaire   +3 more sources

DNA‐PKcs‐Driven YAP1 Phosphorylation and Nuclear Translocation: a Key Regulator of Ferroptosis in Hyperglycemia‐Induced Cardiac Dysfunction in Type 1 Diabetes

Advanced Science, EarlyView.
In the context of chronic hyperglycemia, a DDR is initiated, leading to the pathological activation of DNA‐PKcs in the diabetic heart. This activated DNA‐PKcs directly interacts with and phosphorylates YAP1 at Thr226, thereby increasing the nuclear expression of YAP1.
Junyan Wang, Xing Chang, Chun Li, Jing Gao, Zhijiang Guo, Haowen Zhuang, Lingjun Wang, Yusheng Huang, Wei Wang, Chao Li, Qingyong He   +10 more
wiley   +1 more source

Evaluation of code-based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases

Pulmonary Circulation, 2020
Large administrative healthcare (including insurance claims) databases are used for various retrospective real-world evidence studies. However, in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, identifying patients ...
Viviane P. Sprecher, Eva-Maria Didden, Joel N. Swerdel, Audrey Muller   +3 more
doaj   +1 more source

Changes in Pulmonary Arterial Wall Mechanical Properties and Lumenal Architecture with Induced Vascular Remodeling [PDF]

, 2004
To explore and quantify pulmonary arterial remodeling we used various methods including micro-CT, high-resolution 3-dimensional x-ray imaging, to examine the structure and function of intact pulmonary vessels in isolated rat lungs.
Dawson, Christopher A, Haworth, Steven Thomas, Heinrich, Amy, Molthen, Robert C.   +3 more
core   +1 more source